Amid takeover talk, SpringWorks scores FDA nod for rare genetic disease treatment Gomekli
After Merck KGaA's recent confirmation that it's in discussions to acquire SpringWorks Therapeutics, the Connecticut rare disease specialist has boosted its value with a new FDA nod.
After Merck KGaA's recent confirmation that it's in discussions to acquire SpringWorks Therapeutics, the Connecticut rare disease specialist has boosted its value with a new FDA nod.
